Background: Diabetic dyslipidemia in type 2 diabetes mellitus is defined by elevated TG levels and decreased HDL-C levels, as well as elevated or normal LDL-C levels. In diabetic dyslipidemia, the addition of saroglitazar to statins may provide comprehensive control of lipid para...
Open access
Research Article10.9734/jammr/2023/v35i235312
Background: Type 2 diabetes mellitus (T2DM) is a progressive disease with multifactorial aetiology. Metformin monotherapy is commonly used as the initial treatment, but is often inadequate in achieving optimal glycaemic control, necessitating the need of second and third-line the...
Open access
Research Article10.9734/jamps/2023/v25i6621
Diabetes is a widely prevalent condition and steadily growing as well. In Indian type 2 diabetic patients have a higher amounts of TG and atherogenic lipid sd-LDL. Atherogenic diabetic dyslipidemia is associated with higher residual CV risk and should be treated with a statin as...
Background: Saroglitazar is dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist and approved for elevated triglyceride (TG) reduction in type 2 diabetes mellitus (T2DM) and Non-alcoholic fatty liver disease in India. This study was conducted to evaluate the effect...
Open access
Research Article10.9734/jammr/2024/v36i95569
Aditya Kapoor, Saumitra Ray, T. R. Muralidharan, Viveka Kumar, Bhupen Desai, Nirmal Kumar, Sameer Muchhala & Kunal Jhaveri·Asian Journal of Cardiology Research·2022
Background: Dual anti-platelet therapy (DAPT) includes aspirin and a P2Y12-receptor antagonist, is the cornerstone of treatment for patients with acute coronary syndrome (ACS). Real-world data on the perception and belief on the use of oral anti-platelets (OAP) for the management...
S. Manoj, Jay Shah, Dilip Kumar, Akshaya Pradhan, Amit B. Kinare, Ashwani Kumar Sharma, M. S. Aditya, Ram Anil Raj, Akhter Amin Raina, Ashish Patel, Biswajit Das, Dipak Suresh Bathe, Sameer Muchhala & Kunal Jhaveri·Cardiology and Angiology: An International Journal·2023
Background and Objective: Cardiovascular disease (CVD) is a significant cause of morbidity and mortality worldwide, with high-risk patients requiring effective management to reduce their risk of cardiovascular events. Bempedoic acid is a novel therapeutic agent recently approved...
Open access
Research Article10.9734/ca/2023/v12i4350